Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,301–7,400 of 15,747
Alrubaie, M., Alkhaldi, M., Zeeshan, S., Rasheed, F., & Lang, T. A. (2025) · Global Health Journal · doi:10.1016/j.glohj.2025.02.001 · Cited by 12
Anzalone, A. J., Sun, J., Vinson, A. J., Beasley, W. H., Hillegass, W. B., Murray, K. A., Hendricks, B. M., Haendel, M. A., Geary, C. R., Bailey, K. L., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279968 · Cited by 10
“Vaccine trials have demonstrated a vaccine efficacy of 95% in reducing breakthrough SARS-CoV-2 infection after a second dose of an mRNA vaccination, though the reported median follow-up was only 2 months [51].”
BackgroundChen, J., Pan, L., Lu, Y. Z., Zhang, T., Xu, D., Yan, S., & Ouyang, Z. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2276624 · Cited by 11
“16,59 The UK has less accumulation in mRNA vaccines compared to the US and Germany, but holds a leading position in other vaccine platforms, with the ChAdOx1 nCOV-19 adenoviral vector vaccine developed by the University of Oxford being widely used worldwide.”
BackgroundResultInfluentialHu, X., Karthigeyan, K. P., Herbek, S. L., Valencia, S. M., Jenks, J. A., Webster, H. S., Miller, I. G., Connors, M., Pollara, J., Andy, C., et al. (2023) · medRxiv · doi:10.1101/2023.08.02.23293386 · Cited by 10
Acceptance Rates of COVID-19 Vaccine Highlight the Need for Targeted Public Health Interventions
Zemer, V. S., Grossman, Z., Cohen, H. A., Hoshen, M. B., Gerstein, M., Yosef, N., Cohen, M., & Ashkenazi, S. (2022) · Vaccines · doi:10.3390/vaccines10081167 · Cited by 12
“BNT162b2 was 95% effective in preventing COVID-19 from 7 days after the second dose [8,9].”
BackgroundKrüttgen, A., Haase, G., Haefner, H., Imöhl, M., & Kleines, M. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.1.96 · Cited by 11
“6% [10] and as non-responders or low-responders to vaccinations are not uncommon in clinical medicine [3].”
BackgroundXue, L., Zhang, C., Yin, Q., Bai, Y., Li, J., & Qiu, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113737 · Cited by 12
Open Science Resources for the Mass Spectrometry-Based Analysis of SARS-CoV-2
Bittremieux, W., Adams, C., Laukens, K., Dorrestein, P. C., & Bandeira, N. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00929 · Cited by 11
Revival of Bioengineered Proteins as Carriers for Nucleic Acids
Scherer, D., Burger, M., & Leroux, J. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00079 · Cited by 10
Barlow, R. S., Jian, K., & Larson, L. (2021) · medRxiv · doi:10.1101/2021.08.30.21262446 · Cited by 11
“Results from phase 3 randomized controlled trials of BNT162b2 and mRNA-1273 demonstrated high two-dose vaccine efficacy (~95%) for preventing SARS-CoV-2 infection and COVID-19 with subsequent high vaccine efficacy at 6 month interim analyses [8-10].”
BackgroundThe forerunners and successful partnerships behind the BioNTech mRNA vaccine
Aygün, I., & Barciszewski, J. (2023) · Journal of Applied Genetics · doi:10.1007/s13353-023-00793-5 · Cited by 11
“Tiny balls of fat called lipid nanoparticles, or LNPs in particular, have been extensively studied and successfully used in the clinic to transport small compounds, siRNA medicines, and mRNA (Akinc et al. 2019; Baden and Hana 2021; Anderson et al. 2020; Polack et al. 2020).”
BackgroundMeasuring concerns about the COVID-19 vaccine among Japanese internet users through search queries
Uehara, M., Fujita, S., Shimizu, N., Liew, K., Wakamiya, S., & Aramaki, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-18307-4 · Cited by 8
“For example, studies on the safety and efficacy of the COVID-19 vaccine reported that elderly people are less likely to have adverse reactions than younger people 19,20 .”
BackgroundSubstantial impact of post-vaccination contacts on cumulative infections during viral epidemics
Rochman, N. D., Wolf, Y. I., & Koonin, E. V. (2021) · F1000Research · doi:10.12688/f1000research.52341.1 · Cited by 11
“The time between vaccination and the acquisition of immunity can be readily approximated from clinical endpoints 26,27 and is likely to be short enough that the societal costs of limiting post-vaccination contact would be outweighed by these benefits.”
COVID‐19 vaccines: what do we know so far?
Dhillon, P., Altmann, D. M., & Male, V. H. (2021) · FEBS Journal · doi:10.1111/febs.16094 · Cited by 12
Iwata‐Yoshikawa, N., Nagata, N., Takaki, H., Matsumoto, M., Suzuki, T., Hasegawa, H., & Seya, T. (2022) · ImmunoHorizons · doi:10.4049/immunohorizons.2200020 · Cited by 10
Bridging the Covid-19 data and the epidemiological model using the time-varying parameter SIRD model
Çakmaklı, C., & Şimşek, Y. (2024) · Journal of Econometrics · doi:10.1016/j.jeconom.2024.105787 · Cited by 16
Salvo, F., Pariente, A., Valnet‐Rabier, M., Drici, M., Cholle, C., Mathieu, C., Singier, A., Bagheri, H., Tebacher, M., Micallef, J., et al. (2023) · Therapies · doi:10.1016/j.therap.2023.03.003 · Cited by 9
“Clinical trials showed impressive efficacy and a safety profile similar to other viral vaccines [1,2].”
Decarreaux, D., Pouquet, M., Souty, C., Vilcu, A., Prévot-Monsacre, P., Fourié, T., Villarroel, P. M. S., Priet, S., Blanché, H., Sébaoun, J.-M., et al. (2022) · Viruses · doi:10.3390/v14050957 · Cited by 10
Simoncelli, E., Conticini, E., Colafrancesco, S., Gattamelata, A., Spinelli, F. R., Garufi, C., Truglia, S., Grazzini, S., Giardina, F., Izzo, R., et al. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/if8nka · Cited by 11
“Consistent with our previous findings (17), and as reported in RCTs (14, 15), an inverse association between AEs occurrence and patients’ age has been detected.”
Sugihara, K., Wakiya, R., Shimada, H., Kameda, T., Nakashima, S., Kato, M., Miyagi, T., Mizusaki, M., Mino, R., Nomura, Y., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9223-21 · Cited by 10
“Although the safety and efficacy of the BNT162b2 messenger ribonucleic acid (mRNA) COVID-19 vaccine has been proven in the general population (1), patients receiving immunosuppressive therapy were excluded from the trial.”
BackgroundApplications of microfluidics in mRNA vaccine development: A review
Fardoost, A., Karimi, K., Govindaraju, H., Jamali, P., & Javanmard, M. (2024) · Biomicrofluidics · doi:10.1063/5.0228447 · Cited by 13
Animal models for studying coronavirus infections and developing antiviral agents and vaccines
Lin, Q., Lu, C., Hong, Y., Li, R., Chen, J., Chen, W., & Chen, J. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105345 · Cited by 11
Terada, M., Kondo, N., Wanifuchi‐Endo, Y., Fujita, T., Asano, T., Hisada, T., Uemoto, Y., Kato, A., Yamanaka, N., Sugiura, H., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06693-2 · Cited by 12
“0% efficacy at preventing COVID-19 including severe disease [1, 2].”
BackgroundVolta, L. G., & Gill, S. I. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100027 · Cited by 19
Wei, Y., Kong, W., Dong, Z., Liu, W., Lu, X., Yang, P., Zhao, J., Feng, J., Wei, Z., Yang, J., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c04665 · Cited by 11
How does biological sex affect the physiological response to nanomaterials?
Yang, J. J., Narayanamurthy, R., Yager, J. Y., & Unsworth, L. D. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101292 · Cited by 11
Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domainsPreprint
Stewart-Jones, G. B. E., Elbashir, S. M., Wu, K., Lee, D. W., Renzi, I., Ying, B., Koch, M., Sein, C. E., Choi, A., Whitener, B. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.07.511319 · Cited by 9
“These vaccines were efficacious in clinical trials, with continued real-world vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related infection, hospitalization, and death (1-4) and also against infection with SARS-CoV-2 variants beta (B.”
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design
Reynolds, M., Secora, A., Joules, A., Albert, L., Brinkley, E., Kwon, T., Mack, C., Toovey, S., & Dreyer, N. (2022) · medRxiv · doi:10.2217/cer-2022-0069 · Cited by 8
Iwata, S., Pollard, A. J., Tada, Y., Omoto, S., Shibata, R. Y., Igarashi, K., Hasegawa, T., Ariyasu, M., & Sonoyama, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-57308-3 · Cited by 8
Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary data
Vietri, M., Albanese, L., Passariello, L., D'Elia, G., Caliendo, G., Molinari, A., & Angelillo, I. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105057 · Cited by 9
Ibrahim, D. S., Kis, Z., Tak, K., Papathanasiou, M. M., Kontoravdi, C., Chachuat, B., & Shah, N. (2021) · Vaccines · doi:10.3390/vaccines9121460 · Cited by 9
Butt, A. A., Peng, Y., Shaikh, O. S., Talisa, V. B., Omer, S. B., & Mayr, F. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad393 · Cited by 9
Carruthers, J. E., Wells, J., Gupta, A. T., Kallon, D., Cox, A., Pina, N., Yaqoob, M. M., & Rajakariar, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.817845 · Cited by 9
Heftdal, L. D., Schultz, M., Lange, T., Knudsen, A. D., Fogh, K., Hasselbalch, R. B., Linander, C. B., Kallemose, T., Bundgaard, H., Grønbæk, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac012 · Cited by 9
Effect of vaccination against Covid-19 one year after its introduction in Brazil
Pércio, J., Cabral, C. M., Fantinato, F. F. S. T., de Assis, D. M., Barrera, L. S. G., & de Araújo, W. N. (2022) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-022-00183-5 · Cited by 15
Neutrophil microvesicles and their role in disease
Dow, R., & Ridger, V. C. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106097 · Cited by 9
Chen, C., Li, J., Zhou, Y., Zhang, Y., Huang, R., Zhang, Y., Li, J., & Chen, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1624290 · Cited by 14
Song, R., Chen, X., Li, B., Zhang, H., Guo, X., Liu, Z., Zou, L., Xiao, L., Lei, C., Mao, F., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28805 · Cited by 11
Effectiveness of a nation-wide COVID-19 vaccination program in MexicoPreprint
Bello-Chavolla, O. Y., Antonio-Villa, N., Valdés-Ferrer, S., Fermín-Martínez, C., Fernández-Chirino, L., Ramírez-García, D., Mancilla-Galindo, J., Kammar-García, A., Ávila-Funes, J., Zúñiga-Gil, C., et al. (2022) · medRxiv · doi:10.1101/2022.04.04.22273330 · Cited by 18
Outcomes of COVID ‐19 in multiple myeloma patients treated with daratumumab
Jin, D., He, J., Wu, W., Han, X., Le, J., Shu, W., Fu, J., Kong, H., Wang, G., Zhou, X., et al. (2023) · Cancer Science · doi:10.1111/cas.16001 · Cited by 8
“40,41 In our study, we analyzed the impact of inactivated vaccines on COVID-19 outcomes.”
BackgroundLiatsos, G. D. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i16.2397 · Cited by 11
Chojecka, D., Pytlos, J., Zawadka, M., Andruszkiewicz, P., Szarpak, Ł., Dzieciątkowski, T., Jaguszewski, M. J., Filipiak, K. J., & Gąsecka, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235667 · Cited by 9
“The efficacy of all vaccines is satisfactory, amounting to 95% for BNT162b2 mRNA [71], 94.”
BackgroundZheng, Y., Shen, P., Xu, B., Chen, Y., Luo, Y., Dai, Y., Hu, Y., & Zhou, Y. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1997297 · Cited by 12
Controlling viral inflammatory lesions by rebalancing immune response patterns
Mulik, S., Berber, E., Sehrawat, S., & Rouse, B. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257192 · Cited by 13
Gumber, L., Gomez, N. E., Hopkins, G. V., Tucis, D., Bartlett, L. G., Ayling, K., Vedhara, K., Steers, G., Chakravorty, M., Rutter, M., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac574 · Cited by 10
Tomioka, K., Uno, K., & Yamada, M. (2023) · Environmental Health and Preventive Medicine · doi:10.1265/ehpm.22-00199 · Cited by 9
“Although it takes about 2 weeks from vaccination to develop immunity [4, 25], the BNT16b2 vaccine has been confirmed to be effective 27 days after the second and booster doses [4, 26, 27].”
Backgroundd’Onofrio, A., Iannelli, M., Marinoschi, G., & Manfredi, P. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111881 · Cited by 11
Can a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle?Preprint
Yu, H., Yang, J., Marziano, V., Deng, X., Guzzetta, G., Zhang, J., Trentini, F., Cai, J., Poletti, P., Zheng, W., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-200069/v1 · Cited by 10
Nazarian, S., Olad, G., Abdolhamidi, R., Motamedi, M. J., Kazemi, R., Kordbacheh, E., Felagari, A., Olad, H., Ahmadi, A., Bahiraee, A., et al. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.06.007 · Cited by 11
“However, older individuals showed a lower neutralizing response compared to younger ones (Walsh et al., 2020; Polack et al., 2020).”
Class switch towards non-inflammatory IgG isotypes after repeated SARS-CoV-2 mRNA vaccination
Irrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Wytopil, M., Schäfer, S., Habenicht, K., Zhong, J., Ssebyatika, G., et al. (2022) · medRxiv · doi:10.1101/2022.07.05.22277189 · Cited by 5
“Both mRNA vaccines showed high efficacies of around 90% in preventing SARS-CoV-2 infections in clinical trials 3,4 and even in real-world scenarios 5–8 .”
BackgroundResultInfluentialEdelstein, M. L., Wiegler, K. B., Ben-Amram, H., Bar‐Zeev, N., Sussan, C., Asulin, H., Strauss, D., Bathish, Y., Zarka, S., & Jabal, K. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac212 · Cited by 10
Cytomegalovirus Proctitis Developed after COVID-19 Vaccine: A Case Report and Literature Review
Lv, Y., & Chang, Y. (2022) · Vaccines · doi:10.3390/vaccines10091417 · Cited by 9
“[1] An 82-year-old woman Alzheimer’s disease, HBV infection, HCV infection, DM, essential hypertension, osteoarthritis, portal hypertension with esophageal varices, and hepatic cirrhosis with thrombocytopenia Hepatitis C virus reactivation 3 days after COVID-19 using Pfizer– BioNTech COVID-19 vaccine (first dose) Jaun…”
BackgroundMethodHong, W., Hong, L., Peng, D., Huang, Y., He, C., Yang, H. J., Zhou, Y., Liu, J., Pan, X., Que, H., et al. (2024) · MedComm · doi:10.1002/mco2.539 · Cited by 10
The Impact of Epidemiology on Fertility and Prenatal Care During the COVID-19 Pandemic
Dionne‐Odom, J., & Klipstein, S. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab026 · Cited by 10
TLR7-Adjuvanted Ionizable Lipid Nanoparticles for mRNA Vaccine Delivery
Misra, B., Hughes, K. A., Pentz, W. H., Surface, M., Geldenhuys, W. J., & Bobbala, S. K. R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01073-2 · Cited by 12
“Ionizable lipids remain neutral at physiological pH but acquire a positive charge through protonation in acidic (pH 4–5) endolysosomes of immune cells, promoting the destabilization of the endolysosomal membrane and the release of mRNA into the cytoplasm (1–5).”
Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States
Au, J. (2022) · Infection · doi:10.1007/s15010-022-01802-1 · Cited by 10
Mancuso, K., Zamagni, E., Solli, V., Gabrielli, L., Leone, M., Pantani, L., Rocchi, S., Rizzello, I., Tacchetti, P., Ghibellini, S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1208741 · Cited by 11
“Lines of therapy received, median (range) 1 (1-11)”
BackgroundNiazi, S. K. (2025) · Biomedicines · doi:10.3390/biomedicines13010097 · Cited by 14
Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS
Forte, E., Soye, B. J. D., Melani, R. D., Hollas, M. A. R., Kafader, J. O., Sha, B. E., Schneider, J. R., & Kelleher, N. L. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00514 · Cited by 8
Qualifying coronavirus disease 2019 convalescent plasma donors in Israel
Izak, M., Gendelman, V., Bransburg‐Zabary, S., Stoyanov, E., Gat, R., Cohen, D., Chen, J., Maor, ., Benov, A., Lev, B. I., et al. (2021) · Vox Sanguinis · doi:10.1111/vox.13162 · Cited by 8
“nated in Israel by the Pfizer-BioNTech vaccine [39], urgent requests for CCP units for new COVID-19 patients are being added daily.”
BackgroundAcceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in Japan
Nishida, Y., Hosomi, S., Kobayashi, Y., Nakata, R., Ominami, M., Nadatani, Y., Fukunaga, S., Otani, K., Tanaka, F., Nagami, Y., et al. (2021) · Healthcare · doi:10.3390/healthcare10010006 · Cited by 9
“Vaccines are authorized and recommended to prevent COVID-19 because of their high safety and efficacy [2,3].”
BackgroundAnindita, J., Tanaka, H., Oyama, R., Hagiwara, S., Shirane, D., Taneichi, S., Nakai, Y., Tange, K., Hatakeyama, H., Sakurai, Y., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122702 · Cited by 9
Angleró-Rodríguez, Y., Lempp, F. A., Subramanian, M. P., McIninch, J., Schlegel, M. K., Bohan, D., Wong, E. Y. M., Brown, C. R., Foster, D. J., Castoreno, A. B., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1195 · Cited by 11
Taşkaldıran, I., Altay, F. P., Bozkuş, Y., et al. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220621101209 · Cited by 9
Skorupa, M., Szczepanek, J., Goroncy, A., Jarkiewicz‐Tretyn, J., Ptaszyńska, B., Rajewski, P., Koper, W., Pałgan, K., & Tretyn, A. (2022) · Vaccines · doi:10.3390/vaccines10040506 · Cited by 12
“Importantly, 100 μg of RNA was used in the mRNA-1273 vaccine, while only 30 μg in the BNT162b2 [14,27,28].”
MethodUn caso de nefritis tubulointersticial aguda después de la vacunación con Pfizer-BioNTech COVID-19
de la Flor, J. C., Liñares, T., Alonso, M., Cebollada, P. S., Sierra, C. A., Cícero, E. R., Bayas, G. G., & del Pozo, M. R. (2021) · Nefrología · doi:10.1016/j.nefro.2021.05.004 · Cited by 11
Romero-Pinedo, S., Quesada, M., Horndler, L., Álvarez-Fernández, S., Olmo, A., Abia, D., Alarcón, B., & Delgado, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809285 · Cited by 10
Venturas, J. P. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758852 · Cited by 9
Zheng, Y., Pan, J., Jin, M., Wang, J., Tung, T., Chen, S., Bi, X., Zhou, K., Chen, M., Wang, D., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110151 · Cited by 10
“Several studies have indicated that vaccination can only confer 6–8 months of protective immunity against severe disease and death [7,8].”
Zaman, M., Tiong, D., Saw, J., Zaman, S. J., & Daniels, M. J. (2021) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-021-00901-w · Cited by 9
Vaccine development and technology for SARS‐CoV‐2: Current insight
Cattel, L., Giordano, S., Traina, S., Lupia, T., Corcione, S., Angelone, L., Valle, G. L., Rosa, F. G. D., & Cattel, F. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27425 · Cited by 7
“Between July and November 2020, a Phase 3 multicentric, randomized 1:1 clinical trial was conducted.(19) This efficacy study involved 43 448 participants aged 16–85 or older: 21 720 volunteers received BNT162b2 (30 μg per dose), and 21 728 received a placebo on Days 0 and 21 (Table 2).”
MethodShin, C. H., Kim, K., Jeeva, S., & Kang, S. (2021) · Cells · doi:10.3390/cells10061412 · Cited by 10
Kalnin, K. V., Plitnik, T., Kishko, M., Huang, D., Raillard, A., Piolat, J., Anosova, N. G., Tibbitts, T. J., DiNapoli, J. M., Karve, S., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.021 · Cited by 11
“In summary, our studies showed that a third vaccination administered as a booster, regardless of composition, to the currently approved two dose regimens [49,50] could effectively promote broadly neutralizing antibodies against all variants of concern.”
BackgroundMore than the SRY: The Non-Coding Landscape of the Y Chromosome and Its Importance in Human Disease
Westemeier-Rice, E. S., Winters, M. T., Rawson, T. W., & Martínez, I. (2024) · Non-Coding RNA · doi:10.3390/ncrna10020021 · Cited by 10
“The advent of mRNA vaccines for treatment of SARS-CoV-2 has shown the efficacy of this type of nucleic acid treatment and its potential to help a wide range of diseases [17,18].”
BackgroundNanotechnology in Adjuvants and Vaccine Development: What Should We Know?
Assis, B. R. D., da Silva, C. D., Santiago, M. G., Ferreira, L. A. M., & Goulart, G. A. C. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0360 · Cited by 13
Switchable Lipids: From Conformational Switch to Macroscopic Changes in Lipid Vesicles
Phan, H. T., Gibson, V. P., Guédin, A., Ibarboure, E., Mammeri, N. E., Grélard, A., Meins, J. L., Dufourc, É. J., Loquet, A., Giasson, S., et al. (2023) · Langmuir · doi:10.1021/acs.langmuir.2c03149 · Cited by 10
Jotschke, S., Schulze, S., Jaekel, N., Ludwig‐Kraus, B., Engelmann, R., Kraus, F. B., Zahn, C., Nedlitz, N., Prange‐Krex, G., Mohm, J., et al. (2022) · Cancers · doi:10.3390/cancers14061544 · Cited by 10
Pueyo, P. P., Ruberte, E. G., Ordás, J. G., Blanco, L. M., Pascual-Figal, D. A., Larrañaga-Moreira, J. M., Gómez-Barrado, J. J., Calle, D. G., Bonet, L. A., Salinas, G. L. A., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02225-0 · Cited by 9
Salvaggio, M., Fusina, F., Albani, F., Salvaggio, M., Beschi, R., Ferrari, E., Costa, A. C. S., Agnoletti, L., Facchi, E., & Natalini, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184204 · Cited by 10
“These include lymphadenopathy [1], allergic reactions and anaphylaxis [14], deep vein thrombosis [15], Vaccine–Induced Immune Thrombotic Thrombocytopenia (VITT) [16] and, possibly, death.”
BackgroundLongitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection
Monroe, J. M., Haralambieva, I. H., Warner, N. D., Grill, D. E., Quach, H. Q., & Kennedy, R. B. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11676 · Cited by 12
Miyakawa, K., Kubo, S., Jeremiah, S. S., Go, H., Yamaoka, Y., Ohtake, N., Kato, H., Ikeda, S., Mihara, T., Matsuba, I., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab626 · Cited by 11
“Vaccines are the only limiting modality [1].”
Fang, X., Hu, S., Han, T., Yang, T., Hu, J., Song, Y., Li, C., Ma, A., Li, Y., Kong, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984789 · Cited by 8
“When given inactivated vaccines, the rate of non-epileptic adverse reactions was significantly lower than that of the normal population after adenovirus vector and mRNA vaccination (38, 39).”
BackgroundDrainas, A. P., McIlwain, D. R., Dallas, A. E., Chu, T. P., Delgado‐González, A., Baron, M., Angulo‐Ibáñez, M., Trejo, A., Bai, Y., Hickey, J. W., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01349-0 · Cited by 11
Cosimo, S. D., Lupo-Stanghellini, M., Costantini, M., Mantegazza, R., Ciceri, F., Salvarani, C., Zinzani, P., Mantovani, A., Ciliberto, G., Uccelli, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1002168 · Cited by 8
“For example, in the initial efficacy and safety study of mRNA vaccines (12, 13), younger recipients aged between 16 and 55 years reported systemic events more frequently than their older ≥55 years counterparts (6, 11).”
BackgroundOstroumov, D., Benne, N., Vigario, F. L., Escalona-Rayo, O., Dodz, K., Sauer, S., Suhl, L., Wedemeyer, H. H., Kühnel, F., Slütter, B., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01249-4 · Cited by 12
Shan, W., Xu, J., & Assaraf, Y. G. (2026) · Targetome · doi:10.48130/targetome-0026-0001 · Cited by 11
SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study
Ray, J. G., & Park, A. L. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059944 · Cited by 9
B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
Markewitz, R. D. H., Pauli, D., Dargvainiene, J., Steinhagen, K., Engel, S., Herbst, V., Zapf, D., Krüger, C., Sharifzadeh, S. R., Schomburg, B., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.028 · Cited by 8
“The fact that vaccination with mRNA-1273 leads to higher levels of all examined markers than vaccination with BNT162b2 is most likely explained by the greater amount of mRNA contained in the former (100 mg) compared to the latter (30 mg) [2,3], although it is surprising that this difference is persistent.”
BackgroundModelling the impact of age-stratified public health measures on SARS-CoV-2 transmission in Canada
Gabriele-Rivet, V., Spence, K. L., Ogden, N. H., Fazil, A., Turgeon, P., Otten, A., Waddell, L. A., & Ng, V. (2021) · Royal Society Open Science · doi:10.1098/rsos.210834 · Cited by 11
Datar, R. S., Fette, L. M., Hinkelman, A. N., Hammershaimb, E. A., Friedman-Klabanoff, D. J., Mongraw‐Chaffin, M., Weintraub, W., Ahmed, N., Gibbs, M. A., Runyon, M. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.057 · Cited by 10
Bifurcated monocyte states are predictive of mortality in severe COVID-19Preprint
Cillo, A. R., Somasundaram, A., Shan, F., Cardello, C., Workman, C. J., Kitsios, G. D., Ruffin, A. T., Kunning, S. R., Lampenfeld, C., Onkar, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.10.430499 · Cited by 9
Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice
Wang, Y., Wang, B., Zhao, Z., Xu, J., Zhang, Z., Zhang, J., Chen, Y., Song, X., Zheng, W., Hou, L., et al. (2023) · Viruses · doi:10.3390/v15030763 · Cited by 9
Immune responses to SARS-CoV-2 vaccines in celiac disease
Ibsen, J. H., Chopra, A., Vaage, E. B., et al. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2114809 · Cited by 9
Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response
Verma, A., Manojkumar, A., Dhasmana, A., Tripathi, M. K., Jaggi, M., Chauhan, S. C., Chauhan, D. S., & Yallapu, M. M. (2024) · Nanotheranostics · doi:10.7150/ntno.91910 · Cited by 15
“Commonly reported side effects include headache, fatigue, myalgia, fever, pain, and redness at the injection site (101,132).”
Miao, J., Olson, E., Houlihan, S., et al. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01617-9 · Cited by 9
Lau, Y. H., Lau, K. M., & Ibrahim, N. M. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21034 · Cited by 10
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.